Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

David W. Dawson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0215-5861; OpenAlex author ID A5042354527, A5058489951. Sources: funder_awards.

Their work

Papers
52 (first author 5, last author 5)
Trials
0
Grants
1
Labs led
1
Collaborators
190
Papers, trials and grants by year

2008: 1 grant · 2009: none · 2010: none · 2011: 4 papers · 2012: 4 papers · 2013: 2 papers · 2014: 5 papers · 2015: 7 papers · 2016: 5 papers · 2017: 3 papers · 2018: 2 papers · 2019: none · 2020: none · 2021: 6 papers · 2022: 5 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 4 papers

Papers 50 of 52

  1. Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Co-author DOI 10.1038/s41467-026-68976-2↗
  2. Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug. Co-author DOI 10.1073/pnas.2511733123↗
  3. KDM6 Histone Demethylases Tune Pancreatic Cancer Plasticity. Co-author DOI 10.1158/0008-5472.can-25-3126↗
  4. NEIL2 regulates RNA polymerase II dynamics to suppress transcription–replication conflicts in pancreatic cancer Co-author DOI 10.64898/2026.10.19.760262↗
  5. Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer. Co-author DOI 10.1038/s43018-025-01003-3↗
  6. Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer. Co-author DOI 10.1172/jci.insight.187799↗
  7. Promoter Methylation Leads to Hepatocyte Nuclear Factor 4A Loss and Pancreatic Cancer Aggressiveness. Co-author DOI 10.1016/j.gastha.2024.04.005↗
  8. nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer Co-author DOI 10.1101/2024.09.23.614610↗
  9. Construction of a radiogenomic association map of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-023-10658-z↗
  10. Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade. Co-author DOI 10.1007/s00018-022-04392-1↗
  11. Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Co-author DOI 10.1016/j.celrep.2021.110236↗
  12. Proteomes of Extracellular Vesicles From Pancreatic Cancer Cells and Cancer-Associated Fibroblasts. Co-author DOI 10.1097/mpa.0000000000002115↗
  13. Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-21-0623↗
  14. Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer-Associated Fibroblasts. Co-author DOI 10.1158/2159-8290.cd-21-0601↗
  15. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients. Co-author DOI 10.1002/jso.26279↗
  16. X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biochi.2020.11.018↗
  17. Lysosomal retargeting of Myoferlin mitigates membrane stress to enable pancreatic cancer growth. Co-author DOI 10.1038/s41556-021-00644-7↗
  18. Role of stromal activin A in human pancreatic cancer and metastasis in mice. Co-author DOI 10.1038/s41598-021-87213-y↗
  19. NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. Co-author DOI 10.1073/pnas.2012469118↗
  20. WNT Ligand Dependencies in Pancreatic Cancer. First author DOI 10.3389/fcell.2021.671022↗
  21. Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model. Co-author DOI 10.1038/s41598-018-24337-8↗
  22. KRAS G12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs. Co-author DOI 10.1038/s41598-018-30916-6↗
  23. Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism. Co-author DOI 10.1016/j.surg.2016.12.037↗
  24. Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. Co-author DOI 10.1371/journal.pone.0184455↗
  25. Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. Co-author DOI 10.18632/oncotarget.13572↗
  26. Long-term survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2015.12.024↗
  27. Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. First author DOI 10.1016/j.tem.2016.06.009↗
  28. Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2016.06.032↗
  29. Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000497↗
  30. PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Co-author DOI 10.1101/gad.291021.116↗
  31. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease. Co-author DOI 10.1002/jso.24011↗
  32. p85α is a microRNA target and affects chemosensitivity in pancreatic cancer. Co-author DOI 10.1016/j.jss.2015.02.071↗
  33. Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. First author DOI 10.1038/labinvest.2014.128↗
  34. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Co-author DOI 10.1101/gad.256628.114↗
  35. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Co-author DOI 10.1158/1078-0432.ccr-14-0610↗
  36. Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-15-0204↗
  37. Pancreatic cancer patient survival correlates with DNA methylation of pancreas development genes. Co-author DOI 10.1371/journal.pone.0128814↗
  38. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. Co-author DOI 10.1001/jamasurg.2013.2690↗
  39. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.cell.2014.08.007↗
  40. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncb2916↗
  41. WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma. Last author DOI 10.1038/onc.2013.23↗
  42. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Last author DOI 10.1158/1535-7163.mct-13-1005↗
  43. HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma. Last author DOI 10.1002/cncr.27725↗
  44. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. Co-author DOI 10.1371/journal.pone.0071978↗
  45. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1202490109↗
  46. Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. Co-author DOI 10.1111/j.1440-1746.2011.07013.x↗
  47. Integrative survival-based molecular profiling of human pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-11-1539↗
  48. PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. Co-author DOI 10.1371/journal.pone.0040452↗
  49. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.ajpath.2010.11.058↗
  50. Nodal/Activin signaling: a novel target for pancreatic cancer stem cell therapy. First author DOI 10.1016/j.stem.2011.10.006↗

Grants 1

  1. Wnt Signaling in Pancreatic Cancer Progenitor Cells AWARD pancan:2008-david-dawson-md-phd-wnt-signaling-in-pancreatic-cancer-proge

Closest collaborators

The 25 strongest of 190 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Timothy R. Donahue · 21 shared papers, 2011–2026 · strength 1.71
  2. Oscar Joe Hines · 12 shared papers, 2011–2026 · strength 0.82
  3. Caius Gabriel Radu · 5 shared papers, 2017–2026 · strength 0.63
  4. Guido Eibl · 10 shared papers, 2011–2025 · strength 0.59
  5. Grace Kim · 4 shared papers, 2014–2026 · strength 0.50
  6. Matthias Hebrok · 5 shared papers, 2014–2026 · strength 0.48
  7. Kristina Y. Aguilera · 2 shared papers, 2021–2022 · strength 0.43
  8. Evan R. Abt · 3 shared papers, 2021–2026 · strength 0.42
  9. Rondell Patrell Graham · 2 shared papers, 2025–2026 · strength 0.39
  10. Zev A. Wainberg · 3 shared papers, 2015–2026 · strength 0.38
  11. Jen Jen Yeh · 2 shared papers, 2024–2026 · strength 0.38
  12. Dafna Bar‐Sagi · 2 shared papers, 2025–2026 · strength 0.38
  13. Laura Antonucci · 2 shared papers, 2025–2026 · strength 0.38
  14. Andrew M. Lowy · 2 shared papers, 2025–2026 · strength 0.38
  15. Michael Karin · 2 shared papers, 2025–2026 · strength 0.38
  16. Jonathan C. King · 3 shared papers, 2011–2026 · strength 0.36
  17. Howard A. Reber · 7 shared papers, 2011–2021 · strength 0.35
  18. Audrey M. Hendley · 2 shared papers, 2024–2026 · strength 0.35
  19. Ru Chen · 3 shared papers, 2015–2022 · strength 0.35
  20. Teresa A. Brentnall · 3 shared papers, 2015–2022 · strength 0.35
  21. Mark D. Girgis · 2 shared papers, 2021–2026 · strength 0.34
  22. Jason M. Link · 2 shared papers, 2022–2026 · strength 0.32
  23. Martín E. Fernández-Zapico · 2 shared papers, 2016–2025 · strength 0.31
  24. Hui-Hua Chang · 4 shared papers, 2016–2018 · strength 0.26
  25. Stephen Jacob Pandol · 3 shared papers, 2012–2024 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.